UW Medicine Hospitals:
King County: The county reported 211 new positive cases and 0 new deaths on March 1.
Washington: The state reported 321,881 cases and 4,969 deaths as of Feb. 28.
United States: The CDC reports 28,405,925 cases and 511,839 deaths as of March 1.
Global: WHO reports 113,989,973 confirmed COVID-19 cases and 2,531,542 deaths as of March. 2.
Numbers update frequently, please follow links for most up-to-date numbers.
UW Medicine COVID-19 Vaccine Distribution Update
Total Vaccine Doses Administered: 107,026
- Total first dose: 62,383
- Total second dose: 44,64
As of Feb. 28, 2021.
UW Medicine in the News
UW Medicine Newsroom: UW Medicine hits COVID-19 milestones in vaccines, tests
Featuring: Cynthia Dold; Shireesha Dhanireddy, Infectious Diseases; Geoffrey Baird, Laboratory Medicine and Pathology
“‘For the past year, our clinicians, researchers and technicians have given immense effort to keep our community healthy amid this pandemic,’ said Cynthia Dold, associate vice president of clinical operations for UW Medicine. ‘We are tremendously grateful to our staff members, who have contributed energy, expertise and ingenuity. They have worked long hours and shown extraordinary grace in this time of great duress.’ The health system’s first vaccines were administered on Dec. 15, 2020, to first responders and clinical staff. Vaccine clinics were rapidly established at UW Medical Center (Montlake and Northwest campuses), Harborview Medical Center, and Valley Medical Center. Today, vaccine recipients are community members who qualify under Phase 1B of Washington state’s distribution plan.”
KIRO 7: FDA greenlights J & J COVID-19 vaccine
Featuring: Deborah Fuller, Microbiology
“The demand right now is greatly exceeding the vaccine,’ said University of Washington Medicine’s Dr. Deborah Fuller. She spoke just as the Food and Drug Administration was granting emergency use authorization to a third coronavirus vaccine, the single-dose Johnson and Johnson. ‘I think that’s really important to add another vaccine to our mix of candidates that are going to be available,’ said Fuller. Moreover, she says concerns that the Johnson and Johnson vaccine isn’t as effective as the two-dose Pfizer-BioNTech and Moderna are overblown. All three vaccines are alike in the ways that matter, she insists, as they prevent severe disease and death. ‘People always ask me, ‘Which one would you take?’’ said Dr. Fuller. ‘And I always say, ‘I will take the first one that is offered to me.’ I want that protection as soon as possible.’”
KUOW: Seattle’s vaccine effort just got a major boost with mass vaccination site
Featuring: UW Medicine
“So far, Seattle has used its fire department to provide mobile vaccinations for vulnerable populations and people who have difficulty getting to a fixed site. UW Medicine and Swedish Medical Center are starting similar mobile programs and are partnering with the city to help. Swedish is also a partner for the mass vaccination site at Lumen Field, along with First & Goal, Inc. The mass vaccination site at Lumen Field will be open two days a week and will initially administer 5,000 doses each week, serving the region. Officials’ goal is to get that number up to 150,000 per week. The Lumen Field mass vaccination site is expected to open in mid-March. As with the Rainier Beach and West Seattle sites, vaccines are primarily targeted at communities of color and underrepresented groups.”
COVID-19 Literature Report
COVID-19 Literature Situation Report is a daily (M-F) newsletter put together by the Alliance for Pandemic Preparedness that provides a succinct summary of the latest scientific literature related to the COVID-19 pandemic.
Key Takeaways: COVID-19 Literature Situation Report March 1, 2021
- A meta-analysis of randomized clinical trials comparing patients with COVID-19 treated with convalescent plasma versus controls found no significant differences in all-cause mortality, length of hospital stay, mechanical ventilation use, clinical improvement, or clinical deterioration. More.
- Two studies found that individuals previously infected with SARS-CoV-2 showed stronger immune responses after one dose of the Pfizer-BioNTech vaccine compared to individuals with no prior history of infection. More and More.
- A retrospective cohort study of COVID-19 risk among children and adults in households with an index case of COVID-19 found an overall infection risk of 10%, with median time of 3 days after diagnosis of the index case. More.
- The SARS-CoV-2 variant S-614G conferred small increases in binding and replication using in vitro models but large competitive advantages using in vivo models, potentially explaining the increased prevalence of this strain. More.
COVID-19 Literature Surveillance Team, is an affiliated group of medical students, PhDs and physicians keeping up with the latest research on SARS-CoV-2 / COVID-19 by finding the newest articles, reading them, grading their level of evidence and bringing you the bottom line.
Tweet of the Week
Great podcast (10 minutes) with Christopher Murray, director @IHME_UW, and Sanjay Gupta, chief medical correspondent @CNN on the bumpy road to herd immunity. Murray says herd immunity could happen in winter of 2022, and that real issue is variants. https://t.co/Lt1oKzKqe9
— UW Medicine Newsroom (@uwmnewsroom) March 1, 2021